dasatinib accord
accord healthcare s.l.u. - дазатиниб - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - Антинеопластични средства - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.
dasatinib accordpharma
accord healthcare s.l.u. - дазатиниб - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - Антинеопластични средства - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.
entecavir pharmascience international ltd 0,5 mg film - coated tablets
0,5 mg film - coated tablets
entecavir pharmascience international ltd 1 mg film - coated tablets
1 mg film - coated tablets
fulvestrant pharmascience 250 mg solution for injection in prefilled syringe
250 mg solution for injection in prefilled syringe
lenalidomide pharmascience 5 mg hard capsules
5 mg hard capsules
lenalidomide pharmascience 10 mg hard capsules
10 mg hard capsules
lenalidomide pharmascience 15 mg hard capsules
15 mg hard capsules
lenalidomide pharmascience 25 mg hard capsules
25 mg hard capsules
sorafenib pharmascience 200 mg film-coated tablets
200 mg film-coated tablets